Gain Therapeutics (NASDAQ:GANX) Stock Rating Upgraded by Wall Street Zen

Gain Therapeutics (NASDAQ:GANX) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Sunday.

GANX has been the subject of a number of other research reports. Roth Mkm reaffirmed a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Finally, Weiss Ratings lowered Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Gain Therapeutics Stock Performance

Shares of GANX opened at $1.88 on Friday. The firm has a market cap of $80.18 million, a price-to-earnings ratio of -3.24 and a beta of 0.16. The company’s fifty day moving average is $1.84 and its 200-day moving average is $2.25. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). During the same quarter last year, the business posted ($0.16) earnings per share. Equities analysts expect that Gain Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GANX. Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter worth about $39,000. Commonwealth Equity Services LLC acquired a new stake in Gain Therapeutics during the fourth quarter worth about $41,000. Millennium Management LLC acquired a new stake in Gain Therapeutics during the fourth quarter worth about $45,000. Engineers Gate Manager LP acquired a new stake in Gain Therapeutics during the fourth quarter worth about $47,000. Finally, Wealthspire Advisors LLC bought a new position in Gain Therapeutics during the fourth quarter valued at about $54,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.